• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC NEUROMODULATION IMPLANTABLE NEUROSTIMULATOR; STIMULATOR, ELECTRICAL, IMPLANTED, FOR PARKINS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC NEUROMODULATION IMPLANTABLE NEUROSTIMULATOR; STIMULATOR, ELECTRICAL, IMPLANTED, FOR PARKINS Back to Search Results
Model Number NEU_INS_STIMULATOR
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Unspecified Infection (1930)
Event Date 09/13/2021
Event Type  Injury  
Manufacturer Narrative
Concomitant medical products: product id: 3389, lot# unknown, product type: lead.Information references the main component of the system.Other relevant device(s) are: product id: 3389, serial/lot #: unknown, age or date of birth: this value is the average age of the patients reported in the article as specific patients could not be identified.Sex: this value reflects the gender of the majority of the patients reported in the article as specific patients could not be identified.Date of event: please note that this date is based off of the date of publication of the article as the event dates were not provided in the published literature.If information is provided in the future, a supplemental report will be issued.
 
Event Description
Murilo martinez marinho *, lorena broseghini barcelos, michelle hyczy de siqueira tosin, carolina candeias da silva, vanderci borges, henrique ballalai ferraz, ricardo silva centeno.Effect of bilateral deep brain stimulation on the subthalamic nucleus on patients with parkinson¿s disease: an observational and non-blinded study.Doi 10.1016/j.Inat.2021.101380 objective: this study analyzed the influence of subthalamic nucleus deep brain stimulation (dbs) in motor parameters and patients¿ quality of life with parkinson¿s disease (pd) evaluated before and after 12 months of the surgical procedure.Methods: a cohort of 20 patients with pd who underwent dbs implantation in the subthalamic nucleus was included.Pre and on-dbs postoperative data in on and off-medication periods related to motor functions and quality of life, from the application of validated scales, were collected to verify possible relationships between changes in these parameters and the surgical procedure.Results: a significant decrease in the hoehn and yahr scale diseasestage and in the levodopa equivalent dose (p <(><<)> 0.001) was verified in the off-medication period when we compared baseline and post-12 months data.A significant decrease in dyskinesias (p = 0.009) was observed during the on-medication period by evaluating the udysrs scale.Concerning motor functions verified through the updrs-iii scale, it was obtained a significant reduction in total scores (p = 0.001), besides a decrease in rigidity scores for upper and lower limbs (p <(><<)> 0.05) during the on-medication period.During the off-medication period, scores of updrs-iii demonstrated a significant decrease, except for the ones related to speech and amplitude of resting tremor.Regarding the quality-of life assessment, scores obtained from pdq-39 showed that, after 12 months of electrode implantation, there was a significant decrease in mobility, daily living activity, and stigma parameters (p <(><<)> 0.05).Conclusions: results obtained allow us to conclude that dbs of the subthalamic nucleus in patients with pd improves motor function in both on and off-medication periods, improvement of the disease stage in the off-medication period, with no change in the on-medication period, also an improvement in the patient¿s self reported quality of life and a significant reduction in the dose of l-dopa.Reported events: it was reported that 2 patients experienced an infection and had their systems explanted.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
IMPLANTABLE NEUROSTIMULATOR
Type of Device
STIMULATOR, ELECTRICAL, IMPLANTED, FOR PARKINS
Manufacturer (Section D)
MEDTRONIC NEUROMODULATION
7000 central ave ne
minneapolis MN 55432
Manufacturer (Section G)
MEDTRONIC NEUROMODULATION
7000 central ave ne
minneapolis MN 55432
Manufacturer Contact
glen belmer
7000 central avenue ne rcw215
minneapolis, MN 55432
6122713209
MDR Report Key13091195
MDR Text Key288323205
Report Number2182207-2021-02235
Device Sequence Number1
Product Code MHY
Combination Product (y/n)N
Reporter Country CodeBR
PMA/PMN Number
P960009
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Literature
Reporter Occupation Other
Type of Report Initial
Report Date 12/27/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberNEU_INS_STIMULATOR
Device Catalogue NumberNEU_INS_STIMULATOR
Was Device Available for Evaluation? No
Initial Date Manufacturer Received 11/30/2021
Initial Date FDA Received12/27/2021
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age42 YR
Patient SexMale
-
-